iRhythm Technologies, Inc. (IRTC)
NASDAQ: IRTC · Real-Time Price · USD
169.98
-1.49 (-0.87%)
At close: Aug 29, 2025, 4:00 PM
169.98
0.00 (0.00%)
After-hours: Aug 29, 2025, 4:20 PM EDT
iRhythm Technologies Revenue
iRhythm Technologies had revenue of $186.69M in the quarter ending June 30, 2025, with 26.10% growth. This brings the company's revenue in the last twelve months to $657.23M, up 22.37% year-over-year. In the year 2024, iRhythm Technologies had annual revenue of $591.84M with 20.13% growth.
Revenue (ttm)
$657.23M
Revenue Growth
+22.37%
P/S Ratio
8.23
Revenue / Employee
$328,614
Employees
2,000
Market Cap
5.46B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 591.84M | 99.16M | 20.13% |
| Dec 31, 2023 | 492.68M | 81.76M | 19.90% |
| Dec 31, 2022 | 410.92M | 88.10M | 27.29% |
| Dec 31, 2021 | 322.83M | 57.66M | 21.74% |
| Dec 31, 2020 | 265.17M | 50.61M | 23.59% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
IRTC News
- 11 hours ago - AMALFI Randomized Clinical Trial Results Demonstrate Increased Atrial Fibrillation Diagnosis with Home-Based Long-Term Continuous ECG Monitoring Using iRhythm Technologies' Zio LTCM Service - GlobeNewsWire
- 9 days ago - iRhythm Technologies to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 11 days ago - Investor Short Report Flags Steep Downside Risk For iRhythm Technologies - Benzinga
- 11 days ago - AVALON Real-World Evidence Builds on CAMELOT Study Reinforcing iRhythm's Zio LTCM Clinical Superiority - GlobeNewsWire
- 4 weeks ago - iRhythm Technologies, Inc. (IRTC) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - iRhythm Technologies Announces Second Quarter 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - IRHYTHM INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of iRhythm Technologies, Inc. - IRTC - Business Wire
- 6 weeks ago - iRhythm Technologies to Report Second Quarter 2025 Financial Results on July 31, 2025 - GlobeNewsWire